However, of the 6 biopsied patients with both tumor p16 IHC and CDKN2A promoter methylation data available, 5 demonstrated increases in CDKN2A hypomethylation, yet only 1 of these showed increased p16 expression by IHC. This evidence concerns the gene CDKN2A and neoplasm.